Abstract
Cancer patients, though frequently entering complete remission after successful surgery, and/or irradiation, and chemotherapy years or even decades later may exhibit overt metastases and aggressive, mostly fatal recurrence on the basis of clinically silent persistence of disseminated tumor cells. Cellular dormancy is a mode of hibernation/ inactivity caused by a temporary mitotic arrest. It represents the critical phenomenon of latency making metastatic cancer cells highly refractory to conventional therapies. Regarding host-tumor interactions a broad range of dynamic, interrelated molecular events may influence the dormancy state of quiescence, like regulators of cell cycle arrest, stress signaling pathways, autophagy, microenvironmental, angiogenic and immunologic factors, genetic and epigenetic effects. Nonetheless, the underlying mechanisms are still poorly understood. Moreover, a distinct subset of circulating and disseminated cancer cells exhibits stem cell-like properties with direct tumor-provoking and metastatis-initiating capacity, being at least partly responsible for the specific dormancy features. In residual disease a future more detailed molecular and phenotypic characterization of disseminated tumor cells could represent the prerequisite not only for prognostic and staging purposes, but for a specific design of therapeutic targeting, as well. By understanding the elusive dormancy signatures of tumor cells, their cell- and context (microenvironment)-dependent modulation should provide novel potential therapeutic approaches to avoid or overcome metastatic cancer relapse.
Keywords: Cancer dormancy, metastasis, stress signals, cell adaptation, quiescence, autophagy, microenvironment, stem cell.
Anti-Cancer Agents in Medicinal Chemistry
Title:Metastatic Cell Dormancy and Re-activation: An Overview on Series of Molecular Events Critical for Cancer Relapse
Volume: 17 Issue: 4
Author(s): Gyorgyi Muzes*Ferenc Sipos
Affiliation:
- 2nd Department of Internal Medicine, Semmelweis University, H-1088 Budapest, Szentkirályi str. 46.,Hungary
Keywords: Cancer dormancy, metastasis, stress signals, cell adaptation, quiescence, autophagy, microenvironment, stem cell.
Abstract: Cancer patients, though frequently entering complete remission after successful surgery, and/or irradiation, and chemotherapy years or even decades later may exhibit overt metastases and aggressive, mostly fatal recurrence on the basis of clinically silent persistence of disseminated tumor cells. Cellular dormancy is a mode of hibernation/ inactivity caused by a temporary mitotic arrest. It represents the critical phenomenon of latency making metastatic cancer cells highly refractory to conventional therapies. Regarding host-tumor interactions a broad range of dynamic, interrelated molecular events may influence the dormancy state of quiescence, like regulators of cell cycle arrest, stress signaling pathways, autophagy, microenvironmental, angiogenic and immunologic factors, genetic and epigenetic effects. Nonetheless, the underlying mechanisms are still poorly understood. Moreover, a distinct subset of circulating and disseminated cancer cells exhibits stem cell-like properties with direct tumor-provoking and metastatis-initiating capacity, being at least partly responsible for the specific dormancy features. In residual disease a future more detailed molecular and phenotypic characterization of disseminated tumor cells could represent the prerequisite not only for prognostic and staging purposes, but for a specific design of therapeutic targeting, as well. By understanding the elusive dormancy signatures of tumor cells, their cell- and context (microenvironment)-dependent modulation should provide novel potential therapeutic approaches to avoid or overcome metastatic cancer relapse.
Export Options
About this article
Cite this article as:
Muzes Gyorgyi*, Sipos Ferenc, Metastatic Cell Dormancy and Re-activation: An Overview on Series of Molecular Events Critical for Cancer Relapse, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (4) . https://dx.doi.org/10.2174/1871520616666160901145857
DOI https://dx.doi.org/10.2174/1871520616666160901145857 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Collateral Damage Control in Cancer Therapy: Defining the Stem Identity in Gliomas
Current Pharmaceutical Design Virotherapy as An Approach Against Cancer Stem Cells
Current Gene Therapy Therapeutic Effects of Vitamin D in Asthma and Allergy
Mini-Reviews in Medicinal Chemistry Regulation of the PI3K-Akt Network: Current Status and a Promise for the Treatment of Human Diseases
Current Signal Transduction Therapy Pigment Epithelium-Derived Factor Prevents Melanoma Growth via Angiogenesis Inhibition
Current Pharmaceutical Design Bacteriochlorophyll a and Its Derivatives: Chemistry and Perspectives for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry A Functional Scaffold in Marine Alkaloid: An Anticancer Moiety for Human
Current Medicinal Chemistry Tetraplex Binding Molecules as Anti-Cancer Agents
Recent Patents on Anti-Cancer Drug Discovery Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection
Current Cancer Drug Targets Drugging Cell Cycle Kinases in Cancer Therapy
Current Drug Targets Effects of PPARγ Ligands on Vascular Tone
Current Molecular Pharmacology Management of Gene Variants of Unknown Significance: Analysis Method and Risk Assessment of the VHL Mutation p.P81S (c.241C>T)
Current Genomics The Interaction of Histone Deacetylase Inhibitors and DNA Methyltransferase Inhibitors in the Treatment of Human Cancer Cells
Current Medicinal Chemistry - Anti-Cancer Agents Abrogation of the G2 Checkpoint by Inhibition of Wee-1 Kinase Results in Sensitization of p53-Deficient Tumor Cells to DNA-Damaging Agents
Current Clinical Pharmacology Bisacylimidoselenocarbamates Cause G2/M Arrest Associated with the Modulation of CDK1 and Chk2 in Human Breast Cancer MCF-7 Cells
Current Medicinal Chemistry Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics
Current Medicinal Chemistry Recent Progress and Related Patents on the Applications of Bone Marrow-Derived Stem/Progenitor Cells in Regenerative Medicine and Cancer Therapies
Recent Patents on Regenerative Medicine Stress-Activated MAP Kinase Cascades in Cellular Senescence
Current Medicinal Chemistry New Insights into Binding Interfaces of Coagulation Factors V and VIII and their Homologues - Lessons from High Resolution Crystal Structures
Current Protein & Peptide Science Pathology of the HPV-associated Oropharyngeal Carcinoma
Current Cancer Therapy Reviews